healthcare professionals

Navamedic Q2 2021 Results Presentation

Link to webcast
CEO update

“We work systematically to strengthen our core business by delivering growth through the introduction of new products in existing markets and expanding products to new geographies. We have started and will continue the tedious process to increase company value by owning new products and brands. As a third step, we have been and will actively continue to source and evaluate M&A opportunities to deliver sustainable growth with the objective of building Navamedic to a leading Nordic pharmaceutical company with a footprint in North Europe and other selected countries,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

CEO update
Meet us at exhibitions and fairs
Text
Country
Date
Text
Country
Date
NGF
Norway
October 27-29
NGF
Norway
October 27-29
DSAF
Denmark
November 5-6
DSAF
Denmark
November 5-6
DUS
Denmark
November 19-20
DUS
Denmark
November 19-20
The Finnish Metabolic Club
Finland
November 25-26
The Finnish Metabolic Club
Finland
November 25-26
Diabetesforum
Sweden
December 1-3
Diabetesforum
Sweden
December 1-3
Obesitasdagen
Sweden
December 10
Obesitasdagen
Sweden
December 10